NASDAQ$RPTX
Repare Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported initial camonsertib data and advanced pipeline programs.
Repare Therapeutics reported financial results for the first quarter ended March 31, 2023. The company continues to execute clinically and across pipeline programs, including presenting initial clinical data of camonsertib in combination with various PARP inhibitors from the ongoing TRESR and ATTACC trials. They are on track to present initial Phase 1 monotherapy data for RP-6306 in June.
- Presented initial clinical data of camonsertib in combination with PARP inhibitors at AACR conference.
- Camonsertib combination therapy showed 48% CBR across tumor types.
- On track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical trial in June 2023.
- Appointed Susan Molineaux, Ph.D. to Board of Directors and added Daniel Belanger to senior leadership team.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$5.68M
Forward guidance
Repare expects to report initial Phase 1 monotherapy clinical data for RP-6306 for the treatment of molecularly selected advanced solid tumors (MYTHIC) in June 2023. The Company expects to report initial Phase 1 combination therapy clinical data for RP-6306 for the treatment of molecularly selected advanced solid tumors in the fourth quarter of the year.
Tailwinds
- Present initial Phase 1 monotherapy data for RP-6306 in June 2023
- Report initial Phase 1 combination therapy clinical data for RP-6306 in the fourth quarter of the year
- Initiate clinical testing of RP-6306 combination with carboplatin
- Evaluate RP-6306 in patients with selected, advanced cancers receiving standard agents
- Advance preclinical programs into clinical development
Headwinds
- Evolving impact of macroeconomic events on the Company’s business
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials
- Clinical trial site activation or enrollment rates that are lower than expected
- Changes in expected or existing competition
- Changes in the regulatory environment
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro